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A B ST R AC T 
 
 
We aimed at assessing the interaction between visceral adipose tissue (VAT), 
insulin resistance (IR), circulating levels of monocyte chemoattractant protein-1 
(MCP-1) and malondialdehyde (MDA) and the thyroid parameters in obese 
subjects. Methods. Obese subjects without thyroid pathologies or diseases 
associated with systemic inflammation and OS were recruited. Insulinemia, 
visceral fat thickness, metabolic and thyroid parameters were assayed. Circulating 
levels of MCP-1 and MDA were used to quantify inflammation and OS. Results. 
A number of 160 obese subjects were included. The MCP-1 level increased with 
the degree of obesity and HOMA-IR.  MCP 1 was positively associated with anti-
thyroperoxidase antibody (TPOab) levels and the frequency of Hashimoto’s 
thyroiditis (HT). The MDA level was positively correlated with the degree of 
obesity, aspartate aminotransferase and MCP-1. MDA was an independent 
predictor for the occurrence of hypothyroidism. IR patients showed higher fT3 
levels and a positive association between insulin and TPOab levels. Conclusions. 
Systemic inflammation increased with VAT, IR and OS and was correlated with 
the frequency and the severity of HT, suggesting that, in obesity, MCP-1 could be 
part of the etiopathogenesis of autoimmune thyroiditis. MDA was an independent 
risk factor for hypothyroidism; therefore, redox imbalance associated with obesity 
can produce cell damage and thyroid dysfunction. FT3 is increased in IR patients, 
thus being a marker for the severity of metabolic impairment.   
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Obesity has become a public health problem with a 
highly increased prevalence among adults and children. 
Furthermore, the risk of developing a metabolic syndrome 
is higher in patients with obesity; metabolic syndrome is 
the result of the interplay between an unhealthy lifestyle 
and genetic predisposition [1,2].  
There is an interconnection between obesity and altered 
thyroid function [3]. Thus, patients suffering from obesity 
seem to have lower levels of free T4 (fT4) together with a 
higher volume of the thyroid gland compared to those with 
a body mass index (BMI) within normal limits. Moreover, 
the relationship between thyroid nodules and insulin 
resistance (IR) has been established [4]. Several studies 
[5,6] have shown that patients with obesity have a high 
prevalence of thyroid disorders, although the mechanisms 
linking obesity to thyroid pathology are not completely 
understood. IR, low-grade systemic chronic inflammation, 
and increased oxidative stress (OS) associated with obesity 
can directly cause the impairment of thyroid cells and may 
trigger factors for autoimmune thyroiditis [7,8]. 
Additionally, an increased resistance to thyroid 
hormones was established in patients suffering from 
obesity, a condition which significantly improved after 
bariatric surgery together with the improvement of the 
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thyrotroph thyroxine resistance index and the thyroid-
stimulating hormone index [8]. Baseline thyroid 
stimulating hormone (TSH) levels might be related to 
weight-loss after laparoscopic gastric banding. Thus, the 
amount of short-term weight loss after the aforementioned 
procedure is greater in patients with low normal TSH than 
those with normal and high-normal values [9]. 
Visceral adipose tissue (VAT) is a significant 
determinant of IR vi increased production of 
proinflammatory cytokines (leptin, TNFα, IL-6), and 
chemokines such as monocyte chemoattractant protein-1 
(MCP-1). MCP-1 determines monocytes' recruitment and 
their differentiation into macrophages, increasing the 
inflammatory cascade and interfering with local and 
systemic insulin signaling [10]. Although several studies 
have assessed serum MCP-1 levels in patients with fatty 
liver [11] or thyroid diseases [12], not enough data have 
been reported regarding the effect of "low grade" systemic 
inflammation associated with obesity on thyroid morpho-
functioning. The interplay between high sensitive-C 
reactive protein (hs-CRP) levels and subclinical 
hypothyroidism (SH) has also been analyzed in a cross-
sectional study; however, no association between hs-CRP 
and SH was found [13]. 
It is well-known that both hypothyroidism and 
hyperthyroidism determine increased OS, but the 
mechanism by which obesity-associated OS may alter the 
thyroid remains unclear [14]. IR causes mitochondrial 
dysfunction and the activation of microsomal and 
peroxisomal oxidation pathways, generating increased 
reactive oxygen species (ROS) and lipid peroxidation 
products, such as malondialdehyde (MDA) [15]. 
Mitochondrial dysfunction leads to low cellular energy 
reserves and may be involved in the decreased 
transmembrane transport of thyroid hormones with 
impaired intracellular triiodothyronine (T3) and thyroxine 
(T4) levels, which explains the peripheral resistance to 
thyroid hormones observed in obesity [16]. Moreover, 
MDA may directly cause thyroid damage, having a 
systemic proinflammatory and profibrogenic effect 
[17,18]. Furthermore, the metabolic dysfunction related to 
obesity and IR may alter the deiodinase-1 activity with 
decreased intracellular T4-to-T3 conversion and 
intracellular T3 levels, and increased deiodinase-3 
expression, which stimulates T4 conversion to the inactive 
rT3 form, responsible for the occurrence of the “low T3” 
syndrome [19-21]. 
Based on the hypothesis that IR, inflammation and OS 
associated with obesity could be involved in the 
etiopathogenesis of thyroid disorders, this study assesses 
the interaction between metabolic markers, serum MCP-
1&MDA levels and thyroid parameters in subjects with 
obesity. Our research's second objective was to divide the 
subjects with obesity at a cut-off HOMA-IR ≥ 2.5 and 
compare IR to non-IR groups in terms of inflammation, 
redox imbalance, and thyroid parameters, considering IR 
as a marker of severe metabolic impairment. 
Our study's novelty consists of the complex, integrative 
analyses of the associations between metabolic markers, 
systemic inflammation, OS and thyroid parameters, and 
their evaluation as possible risk factors for the changes in 
thyroid morpho-functioning, commonly observed in 
subjects with obesity. 
Materials and Methods 
A cross-sectional, observational study was conducted 
with the recruitment of eligible subjects, using a non-
probabilistic sampling method, i.e. convenient sampling. 
Patients with obesity, presenting from November 2015 to 
December 2017 to the Endocrinology outpatient clinic for 
obesity investigation, were consecutively enrolled. 
Subjects aged >18 years and with a BMI ≥ 30 kg/m2 were 
included in the sample. Patients with previously known 
thyroid disorders or diseases associated with increased 
systemic inflammation and OS, including diabetes 
mellitus, depression, epilepsy, schizophrenia, cancer, 
rheumatoid arthritis, decompensated liver disease, 
congestive heart failure, or chronic renal failure were 
excluded.  
Each patient was informed before recruitment 
regarding the protocol and was asked for written consent in 
order to participate in the study. The study protocol was 
approved by the Ethics Committee of “Iuliu Haţieganu” 
University of Medicine and Pharmacy and aligned with the 
ethical principles in the Declaration of Helsinki. 
All participants underwent clinical, laboratory and 
ultrasound assessments.  
Clinical evaluation 
Demographic (gender, age) data and the 
anthropometric data, weight, height, waist circumference 
(WC) of each participant, were measured and recorded. 
BMI was calculated as the ratio between weight/height2 
(kg/m2). Obesity was considered at BMI values ≥30 kg/m2 
and was classified as degree I (30-34.9 kg/m2), II (35-39.9 
kg/m2), or III (BMI ≥40 kg/m2) [22]. The diagnosis of 
abdominal obesity was established at WC ≥80 cm in 
women and ≥94 cm in men [23]. The same examiner 
performed all the measurements. 
Laboratory investigations 
Blood samples were collected in the morning after 
overnight fasting. The biochemical determinations 
(glycemia, aspartate aminotransferase [AST], alanine 
aminotransferase [ALT], gamma-glutamyl transpeptidase 
[GGT], triglycerides [TG], total cholesterol [TC], HDL-
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cholesterol, and LDL-cholesterol) were performed on an 
automated analyzer (Beckman Coulter Unicell DXC600, 
USA), using specific commercially available kits. Basal 
insulinemia was determined on an automatic analyzer 
(Beckman Coulter Unicell DXI600, USA) by 
chemiluminescence method (CMIA), using a specific kit 
with the serum detection range from 1.9 μIU/mL to 23 
μIU/mL. IR was assessed with the homeostatic model 
assessment IR (HOMA-IR) index, using the following 
formula: HOMA-IR = basal glycemia (mg/dL) × basal 
insulinemia (μIU/mL)/405. A HOMA-IR index ≥2.5 was 
considered as a criterion for IR [24,25]. At this threshold 
value, the study group was divided into two subgroups: 
obese-IR (HOMA-IR≥2.5) and obese non-IR (HOMA-
IR<2.5) and were compared in terms of metabolic 
impairment, inflammation, redox imbalance, and thyroid 
parameters. 
The TSH, fT4, free T3 [fT3], anti-thyroperoxidase 
antibody [TPOab], and anti-thyroglobulin antibody [TGab] 
were evaluated by ELISA on an automated analyzer 
(Beckman Coulter Unicel DXI 600, USA) and specific kits. 
The fT3/fT4 ratio was subsequently calculated and not 
directly determined. The serum MCP-1 as a marker of 
inflammation was measured on a semi-automated analyzer 
(Tecan Trading AG, Switzerland), using the quantitative 
sandwich ELISA method and protocol described in the kit 
with a serum detection range from 31.25 pg/ml to 2,000 
pg/ml. The plasma MDA was measured as a marker of OS, 
using an isocratic high-performance liquid 
chromatography (HPLC) method based on fluorescence 
detection (Shimadzu LC 2010 Chromatographic System) 
and a specific kit (Chromsystems Instruments & Chemicals 
GmbH, Germany). The limit of detection (7.752×10-4 
μmol/L) and quantification (15.48×10-4 μmol/L) was 
determined using the SMAC program. 
Ultrasound evaluation 
The measurement of the abdominal subcutaneous fat 
thickness (SFT, cm) and visceral fat thickness (VFT, cm) 
was performed in all patients using Mindray DC-N3 
Doppler ultrasound with a 5-MHz convex probe. VFT is 
considered a reliable indicator of VAT and was measured 
with the probe located 1 cm above the navel, on the 
xiphoid-umbilical line, both longitudinally and 
transversally, and defined as the distance between the 
white line and the anterior aortic wall, while SFT was 
measured as the distance between the white line and the 
skin [26]. The ultrasound evaluation was performed by the 
same radiologist, who was blinded to the study.  
Statistical analysis 
Statistical analysis was done with Statistics (StatSoft 
v.8, USA). Qualitative data are reported as absolute and 
relative frequencies (%) with 95% confidence interval 
bounds using an exact method [27] provided in squared 
brackets (CI). The Shapiro-Wilk test was applied to assess 
the normality of the measurements and the data were 
expressed as mean (SD=standard deviation) for normally 
distributed data, and median and interquartile range 
(quartile 1 to quartile 3) otherwise. The association 
between the qualitative data was tested with the Chi-square 
test. The comparison between two independent groups was 
performed using Student’s t-test for normally distributed 
data, and Mann-Whitney test otherwise. The comparisons 
between more than two groups were performed with the 
Kruskal-Wallis test. The association between variables was 
evaluated using the Spearman correlation coefficient. P-
values <0.05 were considered significant for the 
comparison between two groups and 0.017 for the 
comparison between three groups. Logistic regression 
analysis was used to test univariate and multivariate 
associations, and the OR (odds ratio) with associated 95% 
confidence intervals were reported.  
Results 
One hundred and sixty patients with a mean age of 
45±12.44 years (range 18–68 years) were included in the 
study. The majority of patients were women (91.25% 
[85.63 to 95.00]). Most frequently, patients were obesity 
degree I (65% [56.88 to 72.50]), while obesity degree II 
was observed in 21.25% [15.00 to 28.12] and degree III in 
13.75% [8.75 to 20.00]. The frequency of IR (HOMA-
IR≥2.5) was 53.75% [45.63 to 61.87]. The prevalence of 
thyroid dysfunction in the studied group was 18.12%, as 
follows: 0.625% had hyperthyroidism and 17.5% had 
hypothyroidism. Autoimmune and non-autoimmune 
hypothyroidism affected 12% and 5.5% of the patients, 
respectively. Hashimoto's thyroiditis (HT) was present in 
24.5% of the patients. 
The summary of the investigated clinical, thyroid, 
metabolic, inflammatory, and OS parameters is presented 
in Table 1.   
Metabolic and thyroid parameters 
A low correlation was identified between the degree of 
obesity (BMI) and the degree of hepatic impairment 
expressed by the GGT level and TSH on the one hand, and 
some blood markers, on the other hand (Table 2). Moderate 
correlations of VFT with some blood markers were also 
identified (Table 2). 
Although the frequency of thyroid disorders increased 
with the degree of obesity (degree I: 27.88%, degree II: 
35.29%, degree III: 36.36%), no significant differences 
between the degrees of obesity and the presence of thyroid 
dysfunction or HT were identified (p > 0.5). 
As expected, the values of VFT (Kruskal-Wallis test: 
19.67, p=0.0001) were significantly different between 
patients with different degrees of obesity (Figure 1).          
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Table 1. Clinical, biochemical, thyroid, inflammatory status, oxidative stress, and ultrasound parameters in the study 
group 
Parameter Value  Parameter Value  
Demographic and clinical  Biochemical 
Age (years)a 45 (12.44)  ALT (IU/L)b 22 (17.00 to 29.25) 
BMI (kg/m2)b  34 (31.83 to 36.88)  AST (IU/L)b 20 (18.00 to 24.00) 
WC (cm)a                                     108 (11.70)  Total cholesterol (mg/dL)a 203 (43.53) 
HC (cm)b                                          110 (106 to 117.25) LDL-cholesterol (mg/dL)a 130 (30.98) 
HDL-cholesterol (mg/dL)a 47 (10.11) 
TSH (µIU/mL)b 1.81 (1.20 to 2.67)  Insulin (µIU/mL)a 12 (6.71) 
fT4 (ng/mL)a 0.79 (0.13)  Glycemia (mg/dL)a 98 (9.87) 
fT3 (ng/mL)a 0.32 (0.04)  HOMA-IRa 2.99 (1.68) 
fT3/fT4ratio(ng/mL)b 0.40 (0.36 to 0.46)  Ultrasound 
TPOab (IU/mL)b 0.95 (0.40 to 5.35)  SFT (cm)b 2.7 (2.5 to 2.98) 
TGab (IU/mL)b 0.35 (0.20 to 0.70)  VFT (cm)a 5.17 (1.03) 
Inflammatory status  Oxidative stress 
MCP-1 (pg/mL)b 31 (24.21 to 56.50)  MDA (µmol/L)b 0.11 (0.07to 0.15) 
    amean (standard deviation)                                                         bmedian (quartile 1 to quartile 3) 
Abbreviations: BMI - body mass index, WC - waist circumference, HC - hip circumference, TSH – thyroid-
stimulating hormone, fT4 - free thyroxine, fT3 - free triiodothyronine, TPOab – anti-thyroperoxidase antibodies, 
TGab – anti-thyroglobulin antibodies, ALT - alanine aminotransferase, AST - aspartate aminotransferase, GGT 
- gamma-glutamyl transpeptidase, TG - triglycerides, LDL-cholesterol - low-density lipoprotein cholesterol, 
HDL-cholesterol - high-density lipoprotein cholesterol, HOMA-IR - homeostatic model assessment insulin 
resistance index, SFT - subcutaneous fat thickness, VFT - visceral fat thickness, MCP-1 - serum monocyte 
chemoattractant protein-1, MDA - malondialdehyde. 
Table 2. Degree of obesity, VFT, GGT and TSH 


















































Abbreviations: HOMA-IR - homeostatic model 
assessment insulin resistance index, ALT - alanine 
aminotransferase, GGT - gamma-glutamyl 
transpeptidase, TG - triglycerides, VFT - visceral fat 
thickness, WC - waist circumference, fT4 - free 
thyroxine, fT3 - free triiodothyronine, TSH – thyroid-
stimulating hormone, TC - total cholesterol.   
 
Table 3. Significant Spearman correlations between 
serum MCP-1, MDA and clinical, metabolic, 
inflammatory status, oxidative stress and thyroid 
parameters 
Parameter     MCP 1        MDA 
ρ P ρ p 
BMI (kg/m2) 0.286 0.0002 0.194 0.01 
Obesity degree 0.268 0.0006 0.140 0.07 
WC (cm) 0.164 0.03 0.174 0.02 
VFT (cm) 0.674 <0.001 -0.042 0.59 
Insulin (µIU/mL) 0.150 0.05 0.049 0.53 
HOMA-IR ≥ 2.5 -0.182 0.02 -0.034 0.66 
TG (mg/dL) 0.306 0.0001 0.155 0.049 
AST (IU/L) 0.039 0.62 0.222 0.005 
TPOab (IU/mL) 0.198 0.012 0.115 0.14 
HT 0.173 0.028 0.110 0.16 
MDA (µmol/L) 0.207 0.008   
Abbreviations: BMI - body mass index, WC - waist 
circumference, VFT - visceral fat thickness, HOMA-
IR - homeostatic model assessment insulin resistance 
index, TG - triglycerides, AST - aspartate 
aminotransferase, TPOab - antithyroperoxidase 
antibodies, HT - Hashimoto’s thyroiditis, MDA - 
malondialdehyde. 
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Systemic inflammation and OS 
The serum MCP-1 level correlated positively with BMI 
(Table 3) and increased with the degrees of obesity 
(Kruskal-Wallis test: 12.24, p=0.002) (Figure 2). 
Moreover, serum MCP-1 level increased with 
abdominal obesity (WC), TG level (Table 3) and at a cut-
off HOMA-IR ≥2.5, serum MCP-1 levels were higher in 
IR versus non-IR patients (Table 3).  
Regarding the association between thyroid parameters, 
serum MCP-1 level correlated significantly with the level 
of TPOab and the frequency of HT (Table 3). 
A tendency for an association between MCP-1 and 
Hashimoto's thyroiditis was evident in the logistic 
regression analysis (CI95% [1.000-1005]; p = 0.071). 
The OS's assessment in the study group revealed that 
serum MDA level increased with BMI and WC, TG, and 
AST, and positively correlated with the systemic 
inflammation expressed by MCP-1 (Table 3). 
Moreover, multiple regression analysis showed that 
MDA is an independent risk factor associated with the 





Figure 1.  The variability of visceral fat thickness 
according to the degree of obesity. The middle line 
represents the median value, the lower line is given 
by the value of the first quartile, and the upper line 
represents the value of the third quartile. 
Figure 2. The variability of serum monocyte 
chemoattractant protein-1 (MCP-1) according to the degrees 
of obesity. The middle line represents the median value, the 
lower line is given by the value of the first quartile, and the 
upper line represents the value of the third quartile. 
Comparison between the IR and non-IR group at 
cut-off HOMA-IR ≥ 2.5  
The group with obesity was divided according to 
HOMA-IR ≥ 2.5 in order to analyze the differences 
between the groups regarding the metabolic impairment, 
the systemic inflammation, OS and the changes in thyroid 
parameters at this threshold value of IR. Table 4 shows the 
differences between IR and non-IR patients. 
Factors significantly associated with IR in the 
univariate analysis included obesity (both in terms of 
degree [BMI] and distribution [WC, VFT]), ALT, GGT, 
and hypertriglyceridemia (Table 4), but the multiple linear 
regression analysis established that only ALT (CI95% 
[1.008-1.074], p=0.01) and VFT (CI95% [1.167-2.331], 
p=0.005) were independent factors associated with IR. 
Additionally, IR patients showed significantly higher 
serum MCP-1 levels than non-IR ones, but no significant 
difference was noticed regarding the MDA level (Table 4). 
Hypothyroidism had a higher frequency of 19.76% 
(n=17) in IR patients versus non-IR patients 14.86% 
(n=11), but the difference did not reach the statistical 
significance threshold (p>0.05). One of the non-IR patients 
had hyperthyroidism, while 23% of the IR and 26% of the 
non-IR patients had HT (p=0.72).  
As shown in Table 4, IR patients showed significantly 
higher fT3 levels than non-IR patients. Moreover, 
insulinemia was positively associated with TPOab level 
(ρ=0.21, p=0.048) and serum fT4 levels correlated 
negatively with TG levels (ρ=-0.2483, p=0.0212) in IR-
patients.  
In the regression analysis, IR proved not to be a risk 
factor for thyroid dysfunction. 
 
Table 4. Clinical, metabolic, inflammatory status, oxidative stress and thyroid parameters according to 
the presence of insulin resistance (IR) 
 HOMA-IR ≥ 2.5 (n=86) HOMA-IR < 2.5 (n=74) P 
Age (years) a 46 (12.38) 44 (12.47) 0.23 
BMI (kg/m2) b  35 (32.90 to 38.44) 32 (31.05 to 34.40) <0.0001 
WC (cm) a 111 (12.39) 104 (9.80) 0.0003 
SFT (cm) b 2.8 (2.64 to 3.15) 2.60 (2.40 to 2.80) <0.0001 
VFT (cm) a 5.43 (0.96) 4.86 (1.02) 0.0004 
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ALT (IU/L) b 24 (18.00 to 35.75) 19 (16.00 to 25.00) 0.001 
AST (IU/L) b 20 (18.00 to 25.00) 20 (17.25 to 23.00) 0.20 
GGT (IU/L) b 19 (16.00 to 28.75) 16 (12.00 to 21.00) 0.002 
TG (mg/dL) b 139 (116.50 to 169.75) 119 (88.50 to 144.75) 0.005 
Total cholesterol (mg/dL) a 206 (49.20) 200 (35.89) 0.37 
LDL-cholesterol (mg/dL) a 133 (32.96) 126 (28.29) 0.16 
HDL-cholesterol (mg/dL) a 46 (10.58) 47 (9.60) 0.93 
MCP-1(pg/mL) a 36 (24.90 to 65.89) 27 (23.75 to 39.78) 0.021 
MDA (µmol/L) 0.11 (0.08 to 0.16) 0.11 (0.07to 0.14) 0.66 
TSH (µIU/mL) a  1.97 (1.30 to 2.68) 1.74 (1.09 to 2.60) 0.21 
fT4 (ng/mL) b 0.80 (0.13) 0.78 (0.12) 0.26 
fT3 (ng/mL) b 0.32 (0.04) 0.28 (0.02) 0.029 
fT3/fT4 ratio a 0.40 (0.36 to 0.45) 0.40 (0.36 to 0.47) 0.83 
TPOab (IU/mL) a 0.70 (0.40 to 2.85) 1.00 (0.40 to 5.50) 0.66 
TGab (IU/mL) a 0.30 (0.10 to 0.50) 0.40 (0.20 to 0.98) 0.14 
amean (standard deviation), Student’s t test for independent samples 
bmedian (quartile 1 to quartile 3), Mann-Whitney test 
Abbreviations: BMI - body mass index, WC - waist circumference, SFT - subcutaneous fat 
thickness, VFT - visceral fat thickness, ALT - alanine aminotransferase, AST - aspartate 
aminotransferase, GGT - gamma-glutamyl transpeptidase, TG - triglycerides, LDL-cholesterol - 
low-density lipoprotein cholesterol, HDL-cholesterol - high-density lipoprotein cholesterol, MCP-1 
- serum monocyte chemoattractant protein-1, MDA - malondialdehyde, TSH - thyroid-stimulating 
hormone, fT4 - free thyroxine, fT3 - free triiodothyronine, TPOab - anti-thyroperoxidase antibodies, 
TGab - anti-thyroglobulin antibodies. 
Discussions 
One of the main findings of our study was that systemic 
inflammation (MCP-1) increased significantly with the 
obesity degree (BMI), abdominal distribution (VFT, WC), 
and IR.  It was also significantly positively correlated with 
the severity (TPOab) and frequency of Hashimoto’s 
thyroiditis in subjects with obesity. In addition, the OS 
expressed by MDA increased significantly with systemic 
inflammation and it was a predictive factor associated with 
the presence of hypothyroidism in the study group of 
patients with obesity.  
These results are consistent with the literature data 
reported and support the idea that increased serum MCP-1 
in patients with obesity may be a direct consequence of 
abdominal obesity and IR [28,29]. The relationship 
between obesity, fT4, MCP-1 and nerve growth factor-β 
(NGF-β) was investigated in a recent study conducted by 
Molnár exclusively on women [30] which demonstrated 
the correlation between high MCP-1, NGF-β levels and 
low serum fT4 levels in women with obesity [30]. 
Likewise, Sartipy et al. revealed increased microRNA 
MCP-1 expression at VAT and an increase of MCP-1 level 
after the induction of hyperinsulinemic status both in vitro 
and in vivo, showing that visceral obesity and IR are the 
causes of increased MCP-1 serum levels [29]. Moreover, 
systemic inflammation triggers altered insulin response, 
making IR both the cause and the effect of systemic 
inflammation in obesity [11,31].  
Regarding the low-grade inflammation associated with 
obesity and the possible thyroid involvement, our study 
revealed a significant correlation between MCP-1 and both 
severity (TPOab level) and HT's frequency in patients with 
obesity, but without any significant association with the 
thyroid function. Although there were no significant 
differences between IR versus non-IR patients regarding 
the frequency of HT, a significant correlation between 
insulinemia and TPOab levels was seen in IR versus non-
IR patients, indicating the possible pathogenetic 
contribution of hyperinsulinism in the production of 
autoantibodies. Several studies support the role of 
inflammatory cytokines in HT etiopathogenesis; MCP-1 
and other cytokines (TNFα, IL-1, INFδ) may induce and 
aggravate autoimmune thyroid diseases through leukocyte 
chemotaxis and the perpetuation of a chronic inflammatory 
response, leading to thyroid cell injury and impaired 
functioning [7,32]. Several researchers [33-35] have 
shown that hyperleptinemia associated with VAT 
accumulation may be a pathogenic link between obesity, 
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immune system changes, and HT by activating the 
inflammatory induction signals in susceptible patients. Our 
study's result is consistent with that of Kokkotou et al. [12], 
which revealed a positive correlation between MCP-1 and 
antithyroid antibodies in HT patients without reporting a 
significant association with the thyroid function. 
Inflammation and OS are closely related processes in 
obesity, and both interfere with insulin signaling, 
modifying the synthesis, activity, and metabolism of 
thyroid hormones [17-19,21]. Our study showed a 
significant association between MDA and the obesity 
degree & distribution (BMI, WC), along with the hepatic 
impairment (AST) and its significant increase with 
systemic inflammation (MCP-1). Instead, no significant 
difference was found in MDA levels related to IR, probably 
because most patients had degree I obesity, which is not 
associated with a significant increase in OS or IR. In 
regression analyses, MDA was an independent factor 
associated with hypothyroidism in the studied obesity 
group. 
The possible mechanism by which OS may alter the 
thyroid function is complex. The balance between oxidants 
and antioxidants is critical for the proper functioning of the 
thyroid gland, and the direct effect of increased ROS in 
thyroid diseases has been investigated by several studies 
[36]. Moreover, reduced cellular energy production 
secondary to mitochondrial dysfunction is associated with 
the decreased transportation of thyroid hormones to the 
cells, leading to the intracellular deficiency of thyroid 
hormones. Redox imbalance can also alter the expression 
and the activity of deiodinases with decreased intracellular 
activation of T4 in T3 and increased production of 
reversed-T3, resulting in “low-T3” syndrome [16].  
Along with the adipose tissue, the liver is the main 
source of ROS in obesity. The increased influx of FFA and 
inflammatory cytokines into the portal vein from VAT 
lipolysis may cause mitochondrial liver dysfunction, 
increased ROS release, promoting necroinflammation and 
aggravating IR, resulting in fatty liver disease (HS/NASH) 
[37].  
The synthesis of thyroid hormone-binding proteins and 
the activation of T4 into T3 (by deiodinase-1) occur in the 
liver, and thus liver dysfunction associated with the 
severity of obesity and IR might influence hepatic T3 
output by altering the transportation of the thyroid 
hormones to the cellular level and their feedback at the 
hypothalamic-pituitary level [38,39]. In this respect, our 
study revealed a significant positive correlation between 
GGT and serum fT4 levels and a negative correlation 
between GGT levels and fT3/fT4 ratio. Moreover, GGT 
levels increased with IR and obesity degree and 
represented cellular response expression against OS 
[40,41]. Along with the positive association between OS 
(MDA) and AST, this supports the effect of liver 
dysfunction on changes in the thyroid parameters observed 
in obesity. 
Regarding the frequency of thyroid dysfunction 
(18.12%) or HT (24.5%), our results are consistent with the 
literature data for patients with obesity [35,42,43], but 
unlike other studies [5,6,34,38] we found no significant 
differences between the degrees of obesity according to the 
IR presence, possibly due to the predominance of degree I 
obesity, which is not accompanied by marked metabolic 
and endocrine changes. 
Consistent with other studies suggesting that fT3 and/or 
fT3/fT4 ratio increase are markers for the severity of 
metabolic damage in patients with obesity, our study 
results show that IR patients exhibited significantly higher 
fT3 levels than non-IR patients. Furthermore, serum TG 
level was significantly higher in IR patients and associated 
with increased VFT and systemic inflammation (MCP-1) 
(which is explained by VAT lipolysis due to IR) and 
negatively correlated with fT4 levels as compared to non-
IR ones. These results are most likely secondary to 
increased deiodinase-2 activity at the VAT level, with 
higher conversion of T4 to T3. The increase in local T3 
production is probably a defense mechanism to limit 
further adipose gain by increasing thermogenesis and 
stimulating the metabolic activity [20]. 
Concerning the association between the thyroid and 
lipid parameters, our study highlighted a significant 
positive correlation between serum TSH and cholesterol 
levels, as hypothyroidism decreases the rate of lipoprotein 
degradation and LDL-cholesterol receptor synthesis. Other 
studies reported similar results regarding the association 
between thyroid hormones and metabolic parameters, 
predictive for the severity of the metabolic impairment 
[33,37,42-44]. 
Study limitations 
Our study's main limitation is the applied non-
probabilistic sampling method that led to the unequal 
distribution of genders in the investigated sample, since it 
is known that women seek medical attention more 
frequently than men. Notwithstanding, the existing data in 
the literature demonstrated the predominance of thyroid 
disorders among the female population [45]. Thus, there 
are a considerable number of studies that have been carried 
out on female population alone [30, 46]. A more accurate 
view could be obtained by investigating subjects with 
obesity from the general population rather than those who 
presented for medical consultations. 
Conclusions 
Systemic inflammation increased with visceral 
adiposity, IR, and was significantly correlated with the 
frequency and the severity (TPOab levels) of HT, 
suggesting that, in obesity, MCP-1 could be part of the 
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etiopathogenesis of autoimmune thyroiditis. OS (MDA) 
increased significantly with systemic inflammation (MCP-
1) and it was an independent risk factor for the occurrence 
of hypothyroidism, sustaining that redox imbalance 
associated with obesity can produce cell damage and 
contribute to the pathophysiology of thyroid dysfunction. 
A significantly increased level of fT3 in insulin-resistant 
vs. non-insulin-resistant patients supports the value of fT3 
as a marker for the severity of metabolic impairments in 
patients with obesity.  
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